Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | DGKA | P23743 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59459 | 0.94 | TSHR (0.50) | TSHRHSD17B10DGKAALDH1A1TP53 | |
| SCHEMBL10898409 | 0.91 | TSHR (0.48) | TSHRHSD17B10DGKAADRA2AADRA1A | |
| SCHEMBL11224122 | 0.91 | TSHR (0.48) | TSHRHSD17B10DGKAADRA2AADRA1A | |
| SCHEMBL11357980 | 0.86 | TSHR (0.43) | TSHRHSD17B10DGKAALDH1A1ADRA2A | |
| SCHEMBL13864201 | 0.86 | TSHR (0.43) | TSHRHSD17B10DGKAALDH1A1TP53 | |
| Cyclohexane SCHEMBL8420400 | 0.86 | TSHR (0.43) | TSHRHSD17B10DGKAALDH1A1ADRA2A | |
| SCHEMBL98638 | 0.86 | TSHR (0.43) | TSHRHSD17B10DGKAALDH1A1TP53 | |
| Ethylene Glycol SCHEMBL1468277 | 0.86 | TSHR (0.43) | TSHRHSD17B10DGKAADRA2AADRA1A | |
| SCHEMBL97649 | 0.86 | TSHR (0.43) | TSHRHSD17B10DGKAALDH1A1TP53 | |
| Cyclopropane SCHEMBL98406 | 0.86 | TSHR (0.43) | TSHRHSD17B10DGKAALDH1A1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117456-A1 | LCE-BASED ARTIFICIAL MUSCLE FIBER AND PREPARATION METHOD AND USE THEREOF | NANJING DRUM TOWER HOSPITAL (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260021142-A1 | HYDROGELS HAVING CONTROLLED HYDROLYTIC DEGRADATION | GEORGIA TECH RES INST (US) | 2026-01-22 | — | — | US | claimed |
| EP-4642651-A1 | PHOSPHINE OXIDE-BASED PHOTOINITIATORS | ARKEMA France (FR) | 2025-11-05 | — | — | EP | claimed |
| EP-4558545-A1 | HYDROGELS HAVING CONTROLLED HYDROLYTIC DEGRADATION | Georgia Tech Research Corporation (US) | 2025-05-28 | — | — | EP | claimed |
| WO-2024141190-A1 | PHOSPHINE OXIDE-BASED PHOTOINITIATORS | ARKEMA FRANCE (FR) | 2024-07-04 | — | — | WO | claimed |
| US-20240216271-A1 | HYDROLYTICALLY DEGRADABLE HYDROGELS AND USES THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2024-07-04 | — | — | US | claimed |
| EP-4351671-A2 | HYDROLYTICALLY DEGRADABLE HYDROGELS AND USES THEREOF | Georgia Tech Research Corporation (US) | 2024-04-17 | — | — | EP | claimed |
| WO-2024020439-A1 | HYDROGELS HAVING CONTROLLED HYDROLYTIC DEGRADATION | GEORGIA TECH RESEARCH CORPORATION (US) | 2024-01-25 | — | — | WO | claimed |
| WO-2022251468-A2 | HYDROLYTICALLY DEGRADABLE HYDROGELS AND USES THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2022-12-01 | — | — | WO | claimed |
| US-10179831-B2 | Amine-catalyzed thiol-curing of epoxide resins | tooz technologies GmbH (DE) | 2019-01-15 | — | — | US | claimed |
| US-20170174823-A1 | AMINE-CATALYZED THIOL-CURING OF EPOXIDE RESINS | tooz technologies GmbH (DE) | 2017-06-22 | — | — | US | claimed |
| US-20140296431-A1 | METHOD FOR PRODUCING POLYURETHANE LENS | HOYA CORPORATION (JP) | 2014-10-02 | — | — | US | claimed |
| EP-2752684-A1 | METHOD FOR PRODUCING POLYURETHANE LENS | Hoya Corporation (JP) | 2014-07-09 | — | — | EP | claimed |
| EP-1131483-B1 | INHIBITION OF PULP AND PAPER YELLOWING USING HYDROXYLAMINES AND OTHER COADDITIVES | CIBA SC HOLDING AG (CH) | 2003-11-05 | — | — | EP | claimed |
| US-6599326-B1 | Composition having reduced loss of brightness and enhanced resistance to yellowing which comprises chemical paper which may still contain traces of lignin and N,N-dialkylhydroxylamine or derivative or salt thereof | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-07-29 | — | — | US | claimed |
| US-20020174964-A1 | Inhibition of pulp and paper yellowing using hydroxylamines and other coadditives | SELTZER RAYMOND (US) | 2002-11-28 | — | — | US | claimed |
| US-20020088574-A1 | INHIBITION OF PULP AND PAPER YELLOWING USING HYDROXYLAMINES AND OTHER COADDITIVES | CIBA SPECIALTY CHEMICALS CORP. | 2002-07-11 | — | — | US | claimed |
| EP-1131483-A1 | INHIBITION OF PULP AND PAPER YELLOWING USING HYDROXYLAMINES AND OTHER COADDITIVES | Ciba SC Holding AG (CH) | 2001-09-12 | — | — | EP | claimed |
| WO-2000024963-A1 | INHIBITION OF PULP AND PAPER YELLOWING USING HYDROXYLAMINES AND OTHER COADDITIVES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-05-04 | — | — | WO | claimed |
| US-4412897-A | POLYVINYL HALIDES, HYDROQUINONE, ORGANOTIN OR ORGANOANTIMONY COMPOUND, MERCAPTAN | ATO CHIMIE (FR) | 1983-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216271-A1 | HYDROLYTICALLY DEGRADABLE HYDROGELS AND USES THEREOF | MMP1, MMP2, IDUA | TSHR 3551/4885HSD17B10 639/4885DGKA 382/4885 |
| US-20260021142-A1 | HYDROGELS HAVING CONTROLLED HYDROLYTIC DEGRADATION | KDM8, PTMS, USP2 | TSHR 1371/4885HSD17B10 802/4885DGKA 4078/4885 |
| US-20260117456-A1 | LCE-BASED ARTIFICIAL MUSCLE FIBER AND PREPARATION METHOD AND USE THEREOF | MYLK2, MYH10, TNNC1 | TSHR 745/4885HSD17B10 3095/4885DGKA 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.